Von Willebrand factor in CHD and stroke: Relationships and therapeutic implications

Current Treatment Options in Cardiovascular Medicine

Volumn 9, Issue 3, 2007, Pages 180-190

  Cooney, Marie Therese ^b   Dudina, Alexandra L ^b   O'Callaghan, Patrick ^b   Graham, Ian M ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CHOLESTEROL; DALTEPARIN; ENOXAPARIN; HEPARIN; HIRUDIN; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE CORONARY SYNDROME; AFRICA; AGE; ARTERY OCCLUSION; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; GENDER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INJURY; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE;

EID: 34447534493     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-007-0011-8     Document Type: Review

References (31)

1. Hollestelle MJ, Thinnes T, Crain K, et al.: Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost 2001, 86:855-861.
2. Ruggeri ZM: von Willebrand factor. J Clin Invest 1997, 99:559-564.
3. Brinkhous KM, Sandberg H, Garris JB, et al.: Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985, 82:8752-8756.
4. Wagner DD: Cell biology of von Willebrand Factor. Annu Rev Cell Biol 1990, 6:217-246.
5. Keightley AM, Lam YM, Brady JN, et al.: Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF: Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999, 93:4277-4283.
6. der Meer IM, Brouwers GJ, Bulk S, et al.: Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 2004, 124:343-347.
7. Bongers TN, de Maat MP, van Goor ML, et al.: High von Willebrand factor levels increase the risk of first ischemic stroke. Influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006, 37:2672-2677.
8. Goto S: Role of von Willebrand factor for the onset of arterial thrombosis. Clin Lab 2001, 47:327-334.
9. Ruggeri Z: Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001, 14:257-279.
10. Fuster W, Bowie EJ, Lewis JC, et al.: Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978, 61:722-730.
11. Nichols TC, Bellinger RL, Reddick MS, et al.: Role of von Willebrand factor in arterial thrombosis. Studies in normal and von Willebrand disease pigs. Circulation 1991, 83:56-64.
12. Folsom AR, Wu KK, Rosamond WD, et al.: Prospective study of markers of haemostatic function with risk of ischemic stroke: the Atherosclerotic Risk in Communities (ARIC) Study Investigators. Circulation 1997, 96:1102-1108.
13. Folsom AR, Rosamond WD, Shahar E, et al.: Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999, 100:736-742.
14. O'Callaghan PA, Fitzgerald, Fogarty J, et al.: New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in Smokers. Eur J Cardiovasc Prev Rehabil 2005, 12:542-547.
15. Smith FB, Lee AJ, Fowkes FGR, et al.: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study. Arterioscler Thromb Vasc Biol 1997, 17:3321-3325.
16. Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
17. Whincup PH, Danesh J, Walker M, et al.: von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002, 23:1764-1770.
18. Conway DS, Pearce LA, Chin BS, et al.: Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107:3141-3145.
19. Conroy RM, Pyorala K, Fitzgerald AP, et al.: Estimation of ten years risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
20. Chambless L, Heiss G, Shahar E, et al.: Prediction of ischemic stroke in the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2004, 160:259-269.
21. Smith A, Patterson C, Yarnell J, et al.: Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke. Circulation 2005, 112:3080-3087.
22. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke. results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
23. Lip GY, Land D, Van Walraven C, Hart RG: Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation stroke. Stroke 2006, 37:2294-2300.
24. Conway DSG, Pearce LA, Chin BSP, et al.: Plasma von Willebrand factor and soluble P-Selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors. Circulation 2002, 106:1962-1967.
25. Collet JP, Montalescot G, Vicaut E, et al.: Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003, 108:392-394.
26. Montalescot G, Philippe F, Ankri A, et al.: Early increase of von Willebrand factor predicts adverse outcomes in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998, 98:294-299.
27. Montalescot G, Collet JP, Lison L, et al.: Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000, 361:110-114.
28. Lee KW, Lip GY, Tayebjee M, et al.: Circulating endothelial cells, von Willebrand factor, interieukin-6 and prognosis in patients with acute coronary syndromes. Blood 2005, 105:526-532.
29. Catto AJ, Carter AM, Barrett JH, et al.: von Willebrand factor and factor VIIIc in acute cerebrovascular disease: relationship to stroke subtype and mortality. Thromb Haemost 1997, 77:1104-1108.
30. Ip JH, Fuster V, Badimon L, et al.: Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990, 15:1667-1687.
31. Cohen M, Demers C, Gurfinkel EP, et al.: Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998, 82:19L-24L.